Abstract: The present disclosure provides methods, drug combinations and kits for treating, ameliorating, reversing and/or preventing a Helicobacter pylori (H. pylori) infection in a patient in need thereof.

Abstract: The present application relates to a pharmaceutical composition comprising sulbactam or a pharmaceutically acceptable salt thereof, avibactam or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, wherein unit dose ratio of said sulbactam or the pharmaceutically acceptable salt thereof and said avibactam or the pharmaceutically acceptable salt thereof is about 8:1 to about 4:1, unit dose of said sulbactam or the pharmaceutically acceptable salt thereof is about 1 g-4 g, and unit dose of said avibactam or the pharmaceutically acceptable salt thereof is about 0.125 g-1 g. The present application also relates to methods of treating bacterial infections using said pharmaceutical composition.

Abstract: The present invention provides a solid dispersion of a rifamycin-nitroimidazole coupling molecule, comprising a rifamycin-nitroimidazole coupling molecule of a structure shown in formula I, a polymer carrier, functional excipient and a solvent. The polymer carrier is selected from one or a combination of more of PVP K30, PVP-VA64, HPC-L, HPMC E3, Soluplus and polymethacrylate. The functional excipient comprise one or a combination of more of sodium lauryl sulfate, meglumine, VE-TPGS and Tween 80. The solid dispersion of the rifamycin-nitroimidazole coupling molecule of the present invention can be used as a formulation of a drug for treating microbial infection.